Compare Invesco Ltd. (IVZ) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Sanofi SA — how do they compare? Invesco Ltd. trades at $29.51 (market cap $13.28B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 7.2× Invesco Ltd.'s market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Sanofi SA for 94 Days on average.
| IVZ | SNY | |
|---|---|---|
Market Cap | $13.28B | $95.18B |
Volume | 3,698,033 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $33.31 | $52.34 |
52-Week Low | $22.44 | $39.51 |
Typical Hold Time | 77 Days | 94 Days |
Enterprise Value | $23.45B | $114.48B |
Dividend Yield | 2.86% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal and mixed earnings history. The company reported a net loss of $281.70 million for 2025, though revenue grew to $6.38 billion. Analyst consensus is a $33.71 price target with no sell ratings, but technical indicators and recent negative profit margins highlight near-term challenges.
The outlook is cautious; while analyst support and a dividend provide some stability, persistent negative profitability and bearish technicals suggest limited upside until earnings improve. Key risks include execution on turning profits positive and market-sensitive revenue streams.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
